Patents by Inventor Stuart Willis Bright

Stuart Willis Bright has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of detecting human IL-21
    Patent number: 11267882
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: March 8, 2022
    Assignee: ELI LILLY AND COMPANY
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • IL-21 ANTIBODIES AND USES THEREOF
    Publication number: 20190233508
    Abstract: Provided are antibodies, or an antigen-binding fragment thereof, that binds human IL-21, These antibodies are useful in immunoassays of IL-21 levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for determining the presence of IL-21 and/or quantifying IL-21 levels, and for diagnostic, prognostic and predictive purpose, and or optimizing therapeutic regimens in patients in which IL-21 signaling is implicated in pathogenesis.
    Type: Application
    Filed: March 24, 2017
    Publication date: August 1, 2019
    Inventors: Stuart Willis Bright, Julian Davies, Andrea Paula Martin, Joshua Dade Poorbaugh, Oliver Schroeder, Karen Leigh Cox, Angus John MacDonald, Xiao-Fen Wang, Sean Edward Sissons
  • ANTIBODIES THAT BIND IL-23
    Publication number: 20170275356
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Application
    Filed: June 1, 2017
    Publication date: September 28, 2017
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Nucleic acids encoding antibodies that bind IL-23
    Patent number: 9688753
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: May 1, 2015
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • ANTIBODIES THAT BIND IL-23
    Publication number: 20150232552
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Application
    Filed: May 1, 2015
    Publication date: August 20, 2015
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • Antibodies that bind to IL-23
    Patent number: 9023358
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: May 5, 2015
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Daniel Scott Girard, Kristine Kay Kikly
  • ANTIBODIES THAT BIND TO IL-23
    Publication number: 20140255422
    Abstract: The present invention provides an antibody that binds to the p19 subunit of human IL-23 and is characterized as having high affinity, selective, and neutralizing properties. The antibody is useful in the treatment or prevention of an autoimmune or inflammatory condition selected from the group consisting of consisting of multiple sclerosis, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, ankylosing spondylitis, graft-versus-host disease, lupus and metabolic syndrome. The antibody is also useful in the treatment of cancer.
    Type: Application
    Filed: March 4, 2014
    Publication date: September 11, 2014
    Applicant: Eli Lilly and Company
    Inventors: CATHERINE BRAUTIGAM BEIDLER, STUART WILLIS BRIGHT, DANIEL SCOTT GIRARD, KRISTINE KAY KIKLY
  • Anti-IL-23 antibodies
    Patent number: 7872102
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
    Type: Grant
    Filed: August 23, 2006
    Date of Patent: January 18, 2011
    Assignee: Eli Lilly and Company
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot
  • Anti-IL-23 Antibodies
    Publication number: 20090240036
    Abstract: The present invention encompasses isolated antibodies, or antigen-binding portions thereof, that specifically bind to the p19 subunit of IL-23. These antibodies, or antigen-binding portions thereof, are high affinity, neutralizing antibodies useful for the treatment of autoimmune disease.
    Type: Application
    Filed: August 23, 2006
    Publication date: September 24, 2009
    Applicant: ELI LILLY AND COMPANY
    Inventors: Catherine Brautigam Beidler, Stuart Willis Bright, Craig Duane Dickinson, Kristine Kay Kikly, David Matthew Marquis, Alain Philippe Vasserot